Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 7:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,335 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NaCl-saline placebo Clear all
Recruiting Phase 4 Interventional Accepts healthy volunteers

CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)

NCT05846399
View directory record Official record
Conditions
Cat Bite, Hand Injuries, Arm Injury, Infection, Bacterial, Anti-bacterial Agents
Interventions
Amoxicillin/clavulanate, Ciprofloxacin, Clindamycin, Placebo (microcrystalline cellulose), Wound management
Drug · Other · Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 12, 2026, 7:14 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Ondansetron Use for Preventing Pruritus in Patients Undergoing Cesarean Section

NCT06297499
View directory record Official record
Conditions
Pruritus Caused by Drug
Interventions
Ondansetron 8mg
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 12, 2026, 7:14 AM EDT
Recruiting Phase 2 Interventional

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

NCT07246863
View directory record Official record
Conditions
Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Interventions
Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
Biological · Other · Drug
Lead sponsor
CatalYm GmbH
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 12, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma

NCT00843193
View directory record Official record
Conditions
Asthma
Interventions
INTRAVENOUS GSK679586, INTRAVENOUS PLACEBO, FLUTICASONE PROPIONATE
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Medford, Oregon • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 12, 2026, 7:14 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder Syndrome

NCT06096597
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome, Painful Bladder Syndrome (PBS)
Interventions
Clarix Flo, Placebo
Drug
Lead sponsor
David Sheyn
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Clevleand, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 12, 2026, 7:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

NCT05477524
View directory record Official record
Conditions
Lyme Disease
Interventions
VLA15, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
5 Years and older
Enrollment
12,546 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
82
States / cities
Essex, Connecticut • Ledyard Center, Connecticut • New London, Connecticut + 67 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 12, 2026, 7:14 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Sjogrens Syndrome Measured by Ultrasound

NCT03411850
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Orencia, Placebo
Biological · Other
Lead sponsor
Arthritis & Rheumatism Associates, P.C.
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 12, 2026, 7:14 AM EDT
Active, not recruiting Phase 3 Interventional

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

NCT04468659
View directory record Official record
Conditions
Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Interventions
Lecanemab, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 12, 2026, 7:14 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

NCT05648110
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
3,882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
130
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 12, 2026, 7:14 AM EDT
Terminated Phase 3 Interventional

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT01083615
View directory record Official record
Conditions
Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer
Interventions
custirsen sodium, isotonic, 0.9% sodium chloride, docetaxel, cabazitaxel, prednisone
Drug
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
20
States / cities
La Verne, California • Fort Lauderdale, Florida • Tampa, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Oct 12, 2026, 7:14 AM EDT
Terminated Phase 3 Interventional Results available

Inositol to Reduce Retinopathy of Prematurity

NCT01954082
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
myo-Inositol 5% Injection, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
12 Hours to 72 Hours
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 12, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3015014 in Healthy Participants With High Cholesterol

NCT01671085
View directory record Official record
Conditions
Healthy Volunteers, Hypercholesterolemia
Interventions
LY3015014, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 12, 2026, 7:14 AM EDT
Terminated Phase 4 Interventional Results available

Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa

NCT00626574
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Epoetin alfa, Saline
Drug
Lead sponsor
University of South Florida
Other
Eligibility
30 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 12, 2026, 7:14 AM EDT
Completed Phase 2 Interventional

A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease

NCT01843790
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
GCS-100, Placebo, Saline
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Tempe, Arizona • La Mesa, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 12, 2026, 7:14 AM EDT
Terminated Phase 2 Interventional

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain

NCT05359133
View directory record Official record
Conditions
Chemotherapy-induced Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
Interventions
Tetrodotoxin, Placebo
Drug
Lead sponsor
Wex Pharmaceuticals Inc.
Industry
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Santa Ana, California • Santa Rosa, California • Port Charlotte, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 12, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules

NCT04440176
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
MenABCWY, Saline
Biological
Lead sponsor
Pfizer
Industry
Eligibility
11 Years to 14 Years
Enrollment
309 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
20
States / cities
Mobile, Alabama • San Diego, California • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 12, 2026, 7:14 AM EDT
Recruiting Not applicable Interventional

Topical Intranasal Anesthetic Block for Reducing the Pain of Botulinum Toxin Injections for Chronic Migraine

NCT07571889
View directory record Official record
Conditions
Pain From onabotulinumtoxinA Injections
Interventions
onabotulinumtoxinA prophylaxis with Lidocaine, OnabotulinumtoxinA prophylaxis with Saline
Procedure
Lead sponsor
Association of Migraine Disorders
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
East Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 12, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury

NCT01597635
View directory record Official record
Conditions
Lung Injury, Acute
Interventions
Dose 1 GSK2586881, Dose 2 GSK2586881, Dose 3 GSK2586881, Dose 4 GSK2586881, Placebo (saline)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Sacramento, California • Chicago, Illinois • Springfield, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 12, 2026, 7:14 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of TAP and Laparoscopic and Robotic Gynecologic Procedures and Obese Women

NCT01866917
View directory record Official record
Conditions
Pain
Interventions
Ropivacaine 0.5% 20cc injectate bilaterally, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 12, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts

NCT02705352
View directory record Official record
Conditions
Ectropion, Skin Neoplasms
Interventions
5-Fluorouracil, Normal saline
Drug · Other
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 12, 2026, 7:14 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Propranolol Rescue of Prolonged Labor

NCT04299438
View directory record Official record
Conditions
Pregnancy, Prolonged
Interventions
Propranolol Hydrochloride, Saline
Drug · Other
Lead sponsor
Lisa Levine
Other
Eligibility
16 Years and older · Female only
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 12, 2026, 7:14 AM EDT
Terminated Phase 2 Interventional Results available

Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

NCT02088632
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Incobotulinumtoxina, Placebo Comparator
Biological · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 12, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human PfSPZ-LARC2 Vaccination/CHMI

NCT06735209
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 12, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

NCT05736107
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9% Sodium Chloride
Drug · Other
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 64 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 12, 2026, 7:14 AM EDT